Impact of a long-acting beta-agonist and an inhaled corticosteroid in COPD patients with moderate airflow obstruction and CV disease or risk: a factorial analysis of the SUMMIT trial

the SUMMIT investigators, P Calverley, J. A. Anderson, R Brook, C Crim, S. Kilbride, F. J. Martinez, David E. Newby, Jorgen Vestbo, J. Yates, B Celli

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

OriginalsprogEngelsk
ArtikelnummerA6802
TidsskriftAmerican Journal of Respiratory and Critical Care Medicine
Vol/bind193
ISSN1073-449X
StatusUdgivet - 7. feb. 2018
Udgivet eksterntJa

Citationsformater

investigators, T. SUMMIT., Calverley, P., Anderson, J. A., Brook, R., Crim, C., Kilbride, S., Martinez, F. J., Newby, D. E., Vestbo, J., Yates, J., & Celli, B. (2018). Impact of a long-acting beta-agonist and an inhaled corticosteroid in COPD patients with moderate airflow obstruction and CV disease or risk: a factorial analysis of the SUMMIT trial. American Journal of Respiratory and Critical Care Medicine, 193, [A6802].